Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Preetesh Jain

Showing results (81-90 of 176) with videos related to

Pageof 18
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 27, 2013
CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemmaOhad Benjamini, Preetesh Jain, Sergej N Konoplev, et al.
American Journal of Hematology|February 17, 2015
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomePreetesh Jain, Michael Keating, Phillip A Thompson, et al.
Leukemia & Lymphoma|February 22, 2018
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemiaUri Rozovski, David M Harris, Ping Li, et al.
Immunologic Research|October 20, 2015
Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytesBarbara Sherry, Preetesh Jain, Pui Yan Chiu, et al.
Oncotarget|September 29, 2018
STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cellsUri Rozovski, David M Harris, Ping Li, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal DysfunctionKoji Sasaki, Amit Lahoti, Elias Jabbour, et al.
Oncotarget|May 17, 2018
STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cellsUri Rozovski, David M Harris, Ping Li, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaKoji Sasaki, Elias Jabbour, Jorge Cortes, et al.
The Lancet. Haematology|October 6, 2015
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyPreetesh Jain, Hagop Kantarjian, Elias Jabbour, et al.
British Journal of Haematology|August 4, 2017
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitorsPreetesh Jain, Rashmi Kanagal-Shamanna, F Anthony San Lucas, et al.
Pageof 18

Showing results (81-90 of 176) with videos related to

Sort By:
Pageof 18
Clinical Lymphoma, Myeloma & Leukemia|June 27, 2013
CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemmaOhad Benjamini, Preetesh Jain, Sergej N Konoplev, et al.
American Journal of Hematology|February 17, 2015
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomePreetesh Jain, Michael Keating, Phillip A Thompson, et al.
Leukemia & Lymphoma|February 22, 2018
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemiaUri Rozovski, David M Harris, Ping Li, et al.
Immunologic Research|October 20, 2015
Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytesBarbara Sherry, Preetesh Jain, Pui Yan Chiu, et al.
Oncotarget|September 29, 2018
STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cellsUri Rozovski, David M Harris, Ping Li, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal DysfunctionKoji Sasaki, Amit Lahoti, Elias Jabbour, et al.
Oncotarget|May 17, 2018
STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cellsUri Rozovski, David M Harris, Ping Li, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaKoji Sasaki, Elias Jabbour, Jorge Cortes, et al.
The Lancet. Haematology|October 6, 2015
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyPreetesh Jain, Hagop Kantarjian, Elias Jabbour, et al.
British Journal of Haematology|August 4, 2017
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitorsPreetesh Jain, Rashmi Kanagal-Shamanna, F Anthony San Lucas, et al.
Pageof 18